Undisclosed RNA transcript – sequence-specific antisense target

The designation 'Undisclosed RNA transcript – sequence-specific antisense target' is a placeholder used in pharmaceutical research and clinical trial registries to refer to a proprietary genetic target whose identity has not been publicly disclosed (Crooke et al., 2021). This terminology is typically associated with the development of antisense oligonucleotides (ASOs), which are synthetic nucleic acids designed to modulate the expression of specific messenger RNA (mRNA) or non-coding RNA transcripts (Ionis Pharmaceuticals, 2024). By binding to the target sequence through Watson-Crick complementarity, ASOs can induce the degradation of the transcript via RNase H1, alter pre-mRNA splicing, or physically block translation (Bennett, 2019). Such targets are often listed in the pipelines of companies like Ionis Pharmaceuticals during early-stage development to protect intellectual property while demonstrating the progress of their therapeutic platforms (Ionis Pharmaceuticals, 2024). While the specific biological function and disease relevance of the target are hidden, the therapeutic intent is generally to reduce the levels of a protein or RNA involved in a pathological process. Safety concerns for drugs targeting these transcripts include potential off-target effects, sequence-specific immunogenicity, and class-related toxicities such as renal accumulation or thrombocytopenia (Chi et al., 2017).

Other names

Undisclosed RNA targetProprietary antisense target

Antisense oligonucleotide-mediated modulation of RNA expression, including RNase H-dependent degradation, translational blockade, or splicing modification (Crooke et al., 2021; Bennett, 2019).